Women Who Are Pregnant or Planning a Pregnancy

**Recommended vaccines during pregnancy**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>All routine inactivated vaccines</td>
<td>May immunize according to routine schedule, taking into consideration risk of potential exposure during pregnancy (e.g., in an outbreak situation). The exception is HPV vaccine which is contraindicated during pregnancy.</td>
</tr>
<tr>
<td>Influenza vaccine</td>
<td>Inactivated influenza vaccine is recommended at any stage of pregnancy. Live attenuated influenza vaccine is contraindicated during pregnancy.</td>
</tr>
<tr>
<td>MMR vaccine C, D</td>
<td>Contraindicated during pregnancy.</td>
</tr>
<tr>
<td>Varicella vaccine D, E</td>
<td>Contraindicated during pregnancy.</td>
</tr>
</tbody>
</table>

Pregnancy is a time when a healthy woman may have more contact with the medical system than at any other time. It is therefore an opportune time to assess her immunization status and administer any appropriate vaccines that will provide protection for both her and the neonate.

Although pregnancy is an immunologically altered state, there are no data to support an inadequate response to vaccines.

There are no data to indicate that any of the currently approved vaccines are teratogenic or embryotoxic, or have resulted in specific adverse pregnancy outcomes.

There are data to support the benefits of antenatal vaccines on the prevention of disease in the neonate. It is well documented that transplacental transfer of maternal antibodies (particularly IgG) occurs during pregnancy, mainly during the final trimester. Maternal IgG has a half-life of about 3-4 weeks in the newborn, waning during the first 6-12 months of life. Routine infant immunization schedules take into account the potential effect of circulating antibody in the infant.

---

B NACI recommends that Tdap vaccine should be offered in every pregnancy irrespective of previous Tdap immunization history. Immunization with Tdap vaccine should be ideally provided between 27-32 weeks of gestation. However this dose is not currently publicly funded in BC.  
C MMR vaccine is recommended postpartum or preconception for susceptible women. Advise women who are immunized to avoid pregnancy for 1 month following immunization. Rubella infection during pregnancy may cause congenital rubella syndrome (CRS), which can cause miscarriage, stillbirth, and fetal malformations. The highest risk of damage to the fetus following maternal infection occurs during the first trimester.  
D Women who receive RhIg postpartum and are eligible for MMR and/or varicella vaccine should generally wait 3 months before being vaccinated with these vaccines. However, if there is a risk of exposure to measles, mumps, rubella, or varicella, a risk of pregnancy in the 3-month postpartum period, or a risk that vaccines may not be given later, MMR and/or varicella vaccines may be given prior to discharge with a 2nd dose at the recommended interval if indicated. If MMR or varicella vaccine is given within 3 months of receipt of RhIg, serologic testing for rubella or varicella should be done 3 months postpartum and at least 1 month after the final dose. Women who have not mounted an antibody response should be revaccinated.  
E Varicella vaccine is recommended postpartum or preconception for susceptible women. Advise women who are immunized to avoid pregnancy for 1 month following immunization.
Women Who Are Pregnant or Planning a Pregnancy

Most inactivated viral and bacterial vaccines, including toxoids, are considered safe during pregnancy and should be administered when indicated. When vaccines are administered in pregnancy there does not appear to be any evidence of increased risk of adverse events following immunization.

Live attenuated vaccines pose a theoretical risk to the fetus. There are occasions when administration of non-routine live vaccine during pregnancy may be considered (e.g., pregnant traveler to a yellow fever endemic region). If a live vaccine is given inadvertently during pregnancy, termination of the pregnancy is not recommended. If a contraindicated vaccine is administered during pregnancy, this may be reported through pregnancy registers maintained by some vaccine manufacturers. Consult the product monograph or vaccine manufacturer’s website for more information.

Immunize pregnant women at any stage of pregnancy during the influenza season (typically spanning November to April). Serious maternal morbidity (namely hospitalization) from influenza infection supports a recommendation for the immunization of healthy pregnant women, since rates of influenza-associated hospitalization increase with increasing length of gestation after the first trimester.

All pregnant women should be evaluated for immunity to rubella and varicella, and in every pregnancy be tested for the presence of HBsAg.

There are no known risks to the fetus if a woman is given Ig preparations during pregnancy.